Search for: "In re P. F." Results 2181 - 2200 of 4,148
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Aug 2022, 1:35 pm by admin
Gelbach does not explain how or why his calculated p-value for the likelihood ratio is roughly half the unadjusted, two-sided p-value for the tertiary outcome from ASCOT-LLA. [read post]
26 Feb 2022, 6:53 pm by admin
In such health-effects litigation, the judicial handling of concepts such as p-values and confidence intervals often went off the rails. [read post]
17 Nov 2018, 12:10 pm by Schachtman
Despite reports of an odd journal here or there “abolishing” p-values, most medical journals continue to require the presentation of either p-values or confidence intervals. [read post]
14 Aug 2018, 2:28 am by Roel van Woudenberg
             La décision T1897/17 rendue par la Chambre 3.4.01 en date du 14 février 2018 considère qu’un acte de recours déposé après l’expiration du délai de deux mois est irrecevable. [read post]
8 Dec 2023, 12:29 pm by ALBERTO HUAPAYA OLIVARES
La República del Perú la aprobó por Resolución Legislativa N° 31386 del 30 de diciembre de 2021 y ratificó mediante Decreto Supremo N° 003-2022-RE del 7 de febrero de 2022. [read post]
15 Jul 2023, 5:55 pm by ALBERTO HUAPAYA OLIVARES
A nivel del Perú fue aprobado por Resolución Legislativa N° 31386, del 30 de diciembre de 2021 y ratificado mediante Decreto Supremo N° 003-2022-RE del 7 de febrero de 2022. [read post]
17 Mar 2009, 3:28 am
Supp. 2d 1029, 1053 (D.Minn. 2007) (observing that "[p]ersonal views on corporate ethics and morality are not expert opinions"); In re Rezulin Prods. [read post]
11 Jun 2010, 8:36 am by Joseph C. McDaniel
Lundin, Chapter 13 Bankruptcy §164.1, p. 164–1, and n. 4 (3d ed. 2000) (hereinafter Lundin (2000 ed.)) [read post]
5 Nov 2016, 5:13 am by Ed. Microjuris.com Puerto Rico
In re Rodríguez Santiago, 157 D.P.R. 26, 31 (2002); In re Pérez Rodríguez, 115 D.P.R. 810, 811 (1984); In re Carreras Rovira y Suárez Zayas, 115 D.P.R. 778, 788 (1984). [read post]
19 Jul 2022, 2:59 pm by Kevin LaCroix
In the following guest post, the authors revisit the question of whether or not securities class action lawsuits against development-stage biotech companies are likelier to survive a motion to dismiss compared to securities suits against other kinds of companies. [read post]
23 Aug 2012, 6:00 am by Bruce E. Boyden
Fab-Lu Ltd., 360 F.2d 1021, 1022 (2d Cir. 1966) (emphasis added). [read post]
7 May 2009, 6:08 am
As the title also indicates, we're not particularly pleased with the outcome.Best involved chemical with the whopper of a name: "2-Propen-1-aminium, N, N-dimethyl-N-2-propenyl-chloride. [read post]